VANCOUVER, British Columbia, July 17, 2021 (GLOBE NEWSWIRE) – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core one“Or the”Business”) Is pleased to announce that Dr. Robert EW Hancock, President of the Company and Chief Executive Officer of its wholly owned subsidiary Vocan Biotechnologies Inc.Vocan”) He will present at a Virtual City Council meeting organized by the Company on Wednesday, August 4, 2021 at 1:30 pm PST / 4:30 pm ET / 10:30 pm CET.
The Virtual City Hall event will feature a presentation by Dr. Hancock on the status of Vocan’s biosynthetic psilocybin production and will include live video from the company’s operating laboratory in Victoria, British Columbia. Dr. Hancock will also answer questions from investors.
“2021 has been an important year for Core One Labs, and our teams have been very focused on building a company that we truly feel sets a precedent in the psychedelic space. Our multifaceted business model envisions a company that addresses the full psychedelic cycle; From research into the development of proprietary products, the development and implementation of appropriate clinical trial research, as well as attending to the treatment needs of clients in their various journeys to achieve sustained mental health well-being,“Said Joel Shacker, CEO of the company.
“This is a vision that each of our team members is committed to and works diligently with. In recent months, the Company has achieved significant milestones, and I am very excited to announce that our Company’s president, visionary of psychedelics as alternative medicines, and world-renowned scientist, Dr. Robert Hancock will be featured at the first The Company’s virtual council of investors to provide all market participants with an in-depth insight into some of our exciting developments.“
About Core One Labs Inc.
Core One is a biotechnology research and technology life sciences company focused on bringing psychedelic drugs to market through novel delivery systems and psychedelic-assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) that dissolves instantly when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, while maintaining excellent bioavailability. The Company intends to continue developing and applying the technology to psychedelic compounds, such as psilocybin. Core One is also interested in medical clinics that maintain a combined database of more than 275,000 patients. Through these clinics, integrating its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for health disorders. mental.
Core One Labs Inc.
FOR MORE INFORMATION, CONTACT:
Preventive Disclaimer Statement:
The Canadian Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this press release.
The information set forth in this press release contains forward-looking statements that are based on assumptions as of the date of this press release. These statements reflect the current estimates, beliefs, intentions and expectations of management. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, but are not limited to: risks and uncertainties related to the company’s limited operating history and the need to comply with strict regulatory regulations. Consequently, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required by applicable securities law, the company does not undertake any obligation to publicly update or review forward-looking information.
Additionally, psilocybin is currently a Schedule III drug under the Controlled Substances and Drugs Act (Canada) and it is a crime to possess substances under the Controlled Substances and Drugs Act (Canada) without prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement with the illegal sale, production or distribution of psychedelic substances in the jurisdictions in which it operates. While Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics for recreational use. Core One does not deal with psychedelic substances, except in laboratory settings and clinical trials conducted within approved regulatory frameworks.